Innovation in Molecular Transmutation™ and Drug Discovery

Our Innovation

OUR INNOVATION STRATEGY

Innovation needs to thrive with a long-term horizon, developed as a core set of platforms, and fostered as the heart of our non-profit Institute.

We ask questions, and promote the development of deep questions into drug discovery science and how traditional medicinal chemical sciences in particular can be harnessed for surprising breakthroughs.

We ask questions about how an FRO (Focused Research Organization) such as our Institute can directly impact the capital efficiency of the pharma/biotech R&D sector.

Such innovation needs to move across boundaries, and innovation as it develops needs to be tempered and refined by the fire of high-urgency medicinal projects. Drug discovery projects are set up both within the internal drug discovery pipeline as well as through partnerships and/or spin-offs and licensing into the for-profit sector.

Thus the benefits, and strengths, of forming affiliated expert investor communities is a vital part of the innovation strategy as well.

OPPORTUNITY & INSIGHT

Institute for Molecular Intelligence™

Powering AI's Fundamental ability to perceive Chemistry

The power of AI in the design and optimization of new medicines is on the cusp of launching into a new era.  Today's deep neural nets are, however, hampered by the use of mere shadows of molecular information, due to the traditions of standard internet languages for representing structure and data.  Hampered by "linear thinking".

Enter a new way to combine chemistry and AI, mintAI™ , our 3D Molecular Intelligence AI platform.

With this platform, we aim for the power of Molecular Transmutation™ a novel capability that will tie together, and allow leaps across, the 3 chemical spaces of

(i) chemical tool compounds in use in leading disease biology research labs,

(ii) published sphere of molecules with documented biochemical activity, and

(iii) highest-caliber sphere of medicinal chemistry output from the past 70 years, the NCEs (New Chemical Entities) with safe and proven in-life efficacy.

Access to molecular behavior in 3D is essential for creative and truly valuable generative 3D molecular design, for example for medicinal R&D, and is directly enabled by the fundamentally novel approaches being championed by the teams within the Institute for Molecular Intelligence™.

CAPABILITIES & DELIVERABLES

The genomes of the target microbes, as well as the genomic networks within disease-mediating pathways in humans, are fed into the Institute’s computational chemogenomics technology and innovative Molecular Transmutation™ technology.

For each disease area, the next steps depend on the relative merits of known disease biology that have prioritized specific protein targets up front, on the hand, or the pathway-based inquiries, to be handled by methodical and productivity-oriented comparative evaluation of targets within the pathway.

In both situations, we employ an enzymatic drugability evaluation that is intrinsic to the Institute’s core methods. For each target thus selected, the methodical drive towards NCEs is then pursued using our mintAI™ platform.

Deliverables include

  • the de novo discovery of bio-active ligands against specific enzyme targets;

  • acceleration of R&D projects towards innovative INDs by a new approach to convert chemical biology discoveries into advanced medicinal NCEs;

  • the core technology applied to scan diverse microbial genomes, or specified disease-relevant human gene networks, in the search for productive (resource efficient) paths towards advanced medicinal NCEs;

  • improving upon and innovating from clinically-proven drug candidates through scaffold hopping.

OUR INNOVATION known as the mintAI™ platform builds on recently established genome scanning enzyme drugability technologies and is now illuminated and empowered with physics-informed drug discovery chemistry AI